Document is current
Any future updates will be listed below
-
Authors
Biewenga, Maaike https://orcid.org/0000-0002-2797-6164
van der Kooij, Monique K.
Wouters, Michel W. J. M.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan Willem B.
Boers-Sonderen, Marye J.
Hospers, Geke A. P.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
Haanen, John B. A. G.
van der Eertwegh, Alfons J. M.
van Hoek, Bart
Kapiteijn, Ellen
-
Funding
Funding for this research was provided by:
Nederlands Instituut voor Onderzoek van de Gezondheidszorg (836002002)
- License Information
-
More Information
Article History
Received: 24 November 2020
Accepted: 25 January 2021
First Online: 25 February 2021
Compliance with ethical standards
:
: M.J. Boers-Sonderen has served as an advisory board member for Bristol-Myers Squibb, Novartis, Merck and Pierre Fabre. G.A.P. Hospers has served as a consultant and/or advisory board member for Amgen, Roche, MSD, BMS, Pfizer, Novartis and Pierre Fabre and has received research grants not related to this paper from BMS and Seerave. All paid to institution. K.P.M. Suijkerbuijk has served as a consultant and/or advisory board member for Bristol-Myers Squibb, Novartis, MSD, Pierre Fabre and AbbVie and received honoraria/research support not related to this paper from Novartis, Roche and MSD. All paid to institution. A.J.M. van den Eertwegh has served as a speaker for Bristol-Myers Squibb and Novartis and as an advisory board member for Bristol-Myers Squibb, MSD oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck and Pierre Fabre and has received research grants not related to this paper from Sanofi, Roche, Bristol-Myers Squibb, TEVA and Idera. All paid to institution. E. Kapiteijn has served as a consultant and/or advisory board member for Bristol-Myers Squibb, Novartis, Merck and Pierre Fabre and has received research grants not related to this paper from Bristol-Myers Squibb. All paid to institution. All other authors have nothing to disclose.
: All advanced melanoma patients in the Netherlands are registered in the Dutch Melanoma Treatment Registry (DMTR). In compliance with Dutch regulations, the medical ethical committee of the Leiden University Medical Center judged that the DMTR was not subject to the Medical Research Involving Human Subjects Act. The research was conducted in accordance with the declaration of Helsinki revised in 2013.
: As the DMTR was not subject to the Medical Research Involving Human Subjects Act, informed consent of participants was not obligatory.
: All authors approved the final version of the article including the authorship list and consented to publication in Hepatology International.
